Physician profile
Brian Klostermann
NPI 1144457169
$663.93
in general payments reported to CMS, 2019-2025
12 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.66 · 2022: $15.31 · 2023: $126 · 2024: $220 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616 · Debt Forgiveness: $17.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.46 |
| Debt Forgiveness | $17.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $126.82 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $109.43 | 2023-2025 | |
| Novo Nordisk INC | $85.98 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Biosense Webster, INC. | $77.27 | 2023 | Carto 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.56 | 2024-2025 | Jardiance |
| Amgen INC. | $58.62 | 2024-2025 | Evenity, Prolia, Repatha |
| Baxter Healthcare | $32.81 | 2022-2023 | |
| Axsome Therapeutics, INC. | $26.79 | 2025 | Symbravo |
| Abbott Laboratories | $24.66 | 2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $15.94 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.39 | 2025 | Caplyta |
| Electromed, INC. | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Klostermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.